This roundtable series reviews treatments in adult patients with multiple myeloma who have progressed on 1 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.
Dosing Considerations for Selinexor in R/R Multiple Myeloma
April 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, discussed considerations when using selinexor with various drug combinations in later-line multiple myeloma therapy. This is the second of 2 articles based on this event.
Physicians Discuss Recommended Therapies for R/R Multiple Myeloma
May 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.
Managing Adverse Events With Selinexor in R/R Multiple Myeloma
June 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
Physicians Discuss Options for Second Relapse in Multiple Myeloma
July 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed the case of a patient who relapsed after receiving first- and second-line regimens for multiple myeloma. This is the first of 2 articles based on this event.
Counseling Patients on Treatment With Selinexor for Multiple Myeloma
August 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, and other physicians discussed how to manage toxicities and counsel patients when using selinexor for relapsed/refractory multiple myeloma.
Supportive Care Methods in Later Lines of Therapy in RRMM
October 3rd 2023In the second article of a 2-part series, Jack Khouri, MD, discusses with a group of physicians what supportive care options, such as anti-nausea medicine and dose modifications, are important when treating a patient with relapsed/refractory in the third-line setting and beyond.
Selinexor-Based Triplet Therapy Improves Outcomes in Certain Patients with RRMM
November 24th 2023In the first article of a 2-part series, Sumit Madan, MD, discusses how the combination of selinexor, bortezomib, and dexamethasone shows superior survival outcomes for patients with relapsed/refractory multiple myeloma that are proteasome inhibitor naive or have high-risk cytogenetics.
Selinexor-Based Triplet Shows Tolerability With Dose Reductions in RRMM
December 20th 2023In the second article of a 2-part series, Sumit Madan, MD, talked about the manageable toxicity profile with the triplet therapy selinexor (Xpovio), bortezomib, and dexamethasone and how dose reductions led to tolerable outcomes in patients with relapsed/refractory multiple myeloma.
Notable Outcomes of Selinexor-Based Triplet Therapy Addressed in RRMM
February 22nd 2024Adam Binder, MD, discusses what he found to be notable from the results of the phase 3 BOSTON trial that looked at the efficacy of selinexor, bortezomib, and dexamethasone triplet therapy for patients with relapsed/refractory multiple myeloma.